Schizophrenia is a debilitating psychiatric disorder that is treated with antipsychotics.
However, despite their efficacy, antipsychotics increase the risk of metabolic disorders in a …

The gut microbiome (GMB) plays an important role in developmental processes and has
been implicated in the etiology of psychiatric disorders. However, the relationship between …

Objective Although a relationship between schizophrenia (SCZ), antipsychotic (AP)
medication, and metabolic dysregulation is now well established, the effect of adiposity is …

Neurodegenerative and mental disorders are a public health burden with pharmacological
treatments of limited efficacy. Organoselenium compounds are receiving great attention in …

Schizophrenia, a serious psychiatric disorder, is among the top 10 global causes of disability
and affects nearly 1% of the world population. Antipsychotics constitute the best treatment for …

Schizophrenia is a chronic mental and behavioral disorder characterized by clusters of
symptoms including hallucinations, delusions, disorganized thoughts and social withdrawal …

The objective of this study was to evaluate how schizophrenia spectrum disorders and
applied long-term (5.1 years) antipsychotic (AP) treatment affect the serum level of …

Schizophrenia typically emerges during adolescence, with progression from an ultra-high
risk state (UHR) to the first episode of psychosis (FEP) followed by a chronic phase. The …

Objective This study aimed to investigate the role of immune dysfunction in the pathogenesis
of schizophrenia through single-cell transcriptome and bulk RNA data analyses. Methods …

Antipsychotic drug (AP)-naïve first-episode psychosis (FEP) patients display premorbid
cognitive dysfunctions and dysglycemia. Brain insulin resistance may link metabolic and …